Isthmin-1 promotes growth and progression of colorectal cancer through the interaction with EGFR and YBX-1
Xin Zhou,Kaini Zhang,Chen Wang,Yunfei Teng,Peihong Yu,Wei Cai,Wenjie Gao,Min Li,Ying Ding,Peng Sun,Fang Chen,Yipin Wang,Juan Ma,Noriaki Maeshige,Xiaoqi Ma,Qingguo Li,Xiubin Liang,Yaqin Zhang,Dongming Su
DOI: https://doi.org/10.1016/j.canlet.2024.216868
IF: 9.756
2024-04-08
Cancer Letters
Abstract:While previous studies have indicated the involvement of Isthmin 1 (ISM1), a secreted protein, in cancer development, the precise mechanisms have remained elusive. In this study, we unveiled that ISM1 is significantly overexpressed in both the blood and tissue samples of colorectal cancer (CRC) patients, correlating with their poor prognosis. Functional experiments demonstrated that enforced ISM1 expression significantly enhances CRC proliferation, migration, invasion and tumor growth. Notably, our investigation reveals an interaction of ISM1 with epidermal growth factor receptor (EGFR), a member of the receptor tyrosine kinase (RTK) family of CRC cells. The binding of ISM1 triggered EGFR activation and initiate downstream signaling pathways. Meanwhile, intracellular ISM1 interacted with Y-box binding protein 1 (YBX1), enhancing its transcriptional regulation on EGFR. Furthermore, our research uncovered the regulation of ISM1 expression by the hypoxia-inducible transcription factor HIF-1α in CRC cells. Mechanistically, we identified HIF-1α as a direct regulator of ISM1, binding to a hypoxia response element on its promoter. This novel mechanism illuminated potential therapeutic targets, offering insights into restraining HIF-1α/ISM1/EGFR-driven CRC progression and metastasis.
oncology
What problem does this paper attempt to address?